Making a difference to the people we help treat by creating value and improving healthcare outcomes through connecting innovative manufacturers with Australasian customers.

Vircell Independent Molecular Controls for infectious diseases testing

Products are for professional/laboratory use only.

AMPLIRUN Main Features

  • Independent third-party control: valid for any molecular testing platform.
  • Purified nucleic acid, complete microbial genome which allows the monitoring of you amplification and detection steps.
  • Any target can be amplified.
  • Precise concentration in copies/μl verified by Digital Droplet PCR (ddPCR).
  • Non-infectious material provided with inactivation certificate.
  • Lyophilized presentation ensures stability and reduces transport costs.
  • Strain and NCBI sequences are available at www.vircell.com.

Why use Vircell AMPLIRUN PCR controls?

  • Quality assurance.
  • Limit of detection and assay specificity.
  • Assay lot-to-lot verification.
  • Assay development, optimization, and validation.
  • Training/trial purposes.
  • Regulatory requirements/accreditation process compliance.

“Controls independent of those produced by the manufacturer of the test or analyzer should be used”.

National Association of Testing Authorities (NATA) Australia. AS 4633 (ISO 15189) – Supplemental Requirements for accreditation in the field of Medical testing.

Explore the AMPLIRUN QC Catalogue

Download Here >

 



Request a Quote

Request Quote

Recent Posts

Fungal Infection – Assays and Controls*

IMMY | Vircell IMMY’s rapid fungal assays and Vircell’s external controls deliver reliable, room temperature diagnostics with built-in quality assurance for streamlined serology workflows. Vircell…

Read full article

Vircell – VirClia Extraction Tube

Discover Vircell’s VirClia Extraction Tube, an innovative pre-dispensed tube featuring a one-step filtering process that eliminates the need for centrifugation, thereby significantly simplifying the pre-analytical…

Read full article

Advancing Sepsis Diagnostics—Journal of Clinical Medicine (JCM), Honors SeptiCyte RAPID* Study

  Immunexpress are delighted to announce that the study, “Validation of SeptiCyte® RAPID to Discriminate Sepsis from Non-Infectious Systemic Inflammation,” has been selected as an Editor’s Choice Paper for 2024 by the Journal of Clinical Medicine (JCM) MDPI Editorial Team. This honour…

Read full article